Metropolis Healthcare Reports Record Cash Flow Amid Mixed Market Performance and Shareholder Returns

Metropolis Healthcare has recently undergone a financial trend adjustment, reflecting a notable improvement in its performance metrics for the quarter ending September 2025. The company's operating cash flow reached a record high of Rs 275.01 crore, while net sales also peaked at Rs 429.19 crore. Additionally, the operating profit to interest ratio stood impressively at 19.05 times, indicating strong profitability relative to its interest obligations. Other key indicators, such as PBDIT and profit before tax, also achieved their highest levels, with figures of Rs 108.23 crore and Rs 70.14 crore, respectively.
However, not all aspects of the company's financial health are robust. The dividend per share remains at Rs 0.00, and the dividend payout ratio is similarly at 0.00%, suggesting a lack of returns to shareholders. Furthermore, the debtors turnover ratio is notably low at 0.84 times, which may indicate challenges in collecting receivables.

In terms of market performance, Metropolis Healthcare's stock has shown mixed results compared to the Sensex. Over the past week, the stock returned 3.33%, contrasting with a decline in the Sensex. However, on a year-to-date basis, the stock has underperformed, with a return of -1.73% compared to the Sensex's 6.84%. Over a three-year period, the company has outperformed the index, achieving a return of 15.97% against the Sensex's 36.97%.